HaemaLogiX has opened patient enrolment for its phase 1 Koala clinical trial at the Peter MacCallum Cancer Centre, marking ...

AstraZeneca has secured US approval for Baxfendy, a first‑in‑class aldosterone synthase inhibitor for adults whose ...

UCB has announced new week 16 results from the phase 3 BE BOLD trial showing that bimekizumab delivered superior joint ...

CellBxHealth has entered a collaboration with AdventHealth for the use of its Parsortix circulating tumour cell platform in ...

Microbiotica has announced positive findings from its phase 1b MELODY‑1 trial of MB097, an oral precision microbiome ...

The Scottish medicines consortium has recommended the reimbursement of enfortumab vedotin with pembrolizumab for adults with ...

Novo Nordisk has presented new sub‑analyses from the phase 3 OASIS 4 trial at ECO2026, showing that oral semaglutide 25mg ...

PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...

The MHRA is establishing a new hub in Northern Ireland to support the region’s fast‑growing life sciences sector, in a move ...

Enterprise Therapeutics has reported that its phase 2 trial of ETD001, an investigational inhaled epithelial sodium channel blocker, met its primary efficacy outcome in people with cystic fibrosis who ...

Asgard Therapeutics has appointed Prof Dr Wolfram Brugger as Chief Medical Officer, strengthening its leadership team as the ...